Document Detail


Effectiveness of adalimumab dose escalation, combination therapy of adalimumab with methotrexate, or both in patients with psoriasis in daily practice.
MedLine Citation:
PMID:  23194389     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
Abstract Abstract To increase effectiveness of standard adalimumab treatment 40mg every other week (EOW) for patients with psoriasis, dose escalation to 40mg every week or addition of methotrexate (MTX) are possible strategies. Methods Daily practice data about adalimumab treatment were extracted from a prospective observational cohort. We analyzed all patients with insufficient efficacy of adalimumab EOW who received (1) adalimumab dose escalation, (2) addition of MTX to adalimumab EOW or (3) both. Effectiveness was analyzed after 12 and 24 weeks using PASI50, PASI75 and mean differences in PASI. Results Forty-seven treatment episodes (TE) of adalimumab dose escalations, 11 of MTX addition and six combinations were analyzed. After a first episode of adalimumab dose escalation, 25% and 35% achieved PASI50 after 12 and 24 weeks respectively. After MTX introduction to adalimumb EOW, 9% and 18% achieved PASI50 after 12 and 24 weeks respectively. No related serious adverse events were reported. Conclusions Twenty-five percent of first TE with adalimumab dose escalation induced a PASI50 response after 12 weeks and 35% after 24 weeks. Addition of MTX to adalimumab EOW resulted in PASI50 in 9% after 12 weeks and 18% after 24 weeks. Defining patient-groups that will benefit from these interventions is important.
Authors:
Juul van den Reek; Paula Pm van Lümig; Wietske Kievit; Jeffrey Zweegers; Peter Cm van de Kerkhof; Marieke Seyger; Elke de Jong
Related Documents :
23097669 - Practical approaches to the use of lenalidomide in multiple myeloma: a canadian consensus.
11345029 - Comparative evaluation of the efficiency of various ukrain doses in the combined treatm...
1102569 - Metiapine: a double-blind comparison with chlorpromazine in acute schizophrenic patients.
20569989 - Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macu...
15278609 - Functional and metabolic effects of propafenone in the rat heart-lung preparation.
7865609 - Response of sows to estradiol benzoate after weaning.
15502029 - The pharmacokinetics of the intravenous formulation of fentanyl citrate administered or...
11537129 - Radiation protection strategies in hermes missions.
7919459 - In vitro antitumor effect of hydroxyurea on hormone-refractory prostate cancer cells an...
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-11-30
Journal Detail:
Title:  The Journal of dermatological treatment     Volume:  -     ISSN:  1471-1753     ISO Abbreviation:  J Dermatolog Treat     Publication Date:  2012 Nov 
Date Detail:
Created Date:  2012-11-30     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8918133     Medline TA:  J Dermatolog Treat     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Department of Dermatology, Radboud University Nijmegen Medical Centre , The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The Relationship Between Some of the Cardiovascular Risk Factors and Arterial Stiffness Parameters i...
Next Document:  The Mononuclear Phagocyte System in Kidney Disease and Repair.